A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components

Journal of Controlled Release

Volumn 214, Issue , 2015, Pages 94-102

  Kinnunen, Hanne M ^a,d   Sharma, Vikas ^b   Contreras Rojas, Luis Rodrigo ^a   Yu, Yafei ^a   Alleman, Chlöe ^a   Sreedhara, Alavattam ^b   Fischer, Stefan ^c   Khawli, Leslie ^b,e   Yohe, Stefan T ^b   Bumbaca, Daniela ^b   Patapoff, Thomas W ^b   Daugherty, Ann L ^b   Mrsny, Randall J ^a  

^a University of Bath   (United Kingdom)

^b GENENTECH INC   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d DURHAM UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biopharmaceuticals; Formulation design; In vitro model; Subcutaneous injection

Indexed keywords

ANIMALS; BIOCHEMISTRY; DRUG PRODUCTS; HYALURONIC ACID; MICROCIRCULATION; MONOCLONAL ANTIBODIES; TISSUE;

BIOPHARMACEUTICALS; ENVIRONMENTAL CHANGE; EXTRACELLULAR MATRICES; FORMULATION DESIGN; IN-VITRO MODELS; PHYSICO-CHEMICAL CHANGES; PHYSIOLOGICAL BUFFERS; REAL TIME MONITORING;

TOOLS;

HYALURONIC ACID; INSULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2; MONOCLONAL ANTIBODY A; MONOCLONAL ANTIBODY F; MONOCLONAL ANTIBODY T; UNCLASSIFIED DRUG; BICARBONATE; BIOLOGICAL PRODUCT; BUFFER;

ARTICLE; DRUG DETERMINATION; DRUG FORMULATION; EVALUATION STUDY; EXTRACELLULAR MATRIX; HUMAN; IN VITRO STUDY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCISSOR SYSTEM; CHEMISTRY; DIALYSIS; DRUG DESIGN; LYMPH; MEDICINAL CHEMISTRY; METABOLISM; SUBCUTANEOUS DRUG ADMINISTRATION; SUBCUTANEOUS TISSUE;

ANTIBODIES, MONOCLONAL; BICARBONATES; BIOLOGICAL PRODUCTS; BUFFERS; CHEMISTRY, PHARMACEUTICAL; DIALYSIS; DRUG DESIGN; EXTRACELLULAR MATRIX; HUMANS; HYALURONIC ACID; INJECTIONS, SUBCUTANEOUS; LYMPH; SUBCUTANEOUS TISSUE;

EID: 84938154073     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.07.016     Document Type: Article

References (31)

1. B. Escudier Metastatic RCC: moving towards a chronic disease Oncology 26 2012 304 (306)
2. X. Pivot, and et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study Lancet Oncol. 14 2013 962 970
3. L. Tang, A.M. Persky, G. Hochhaus, and B. Meibohm Pharmacokinetic aspects of biotechnology products J. Pharm. Sci. 93 2004 2184 2204
4. W. Wang, E.Q. Wang, and J.P. Balthasar Monoclonal antibody pharmacokinetics and pharmacodynamics Clin. Pharmacol. Ther. 84 2008 548 558
5. H. Mach, and T. Arvinte Addressing new analytical challenges in protein formulation development Eur. J. Pharm. Biopharm. 78 2011 196 207
6. H. Bleuel, and et al. Kinetics of subcutaneous versus intravenous epoetin-beta in dogs, rats and mice Pharmacology 52 1996 329 338
7. I.C. Macdougall, D.E. Roberts, G.A. Coles, and J.D. Williams Clinical pharmacokinetics of epoetin (recombinant human erythropoietin) Clin. Pharmacokinet. 20 1991 99 113
8. T. Salmonson, B.G. Danielson, and B. Wikstrom The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects Br. J. Clin. Pharmacol. 29 1990 709 713
9. D.M. Gibson, S. Cotler, H.E. Spiegel, and W.A. Colburn Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog J. Interf. Res. 5 1985 403 408
10. R.J. Wills Clinical pharmacokinetics of interferons Clin. Pharmacokinet. 19 1990 390 399
11. C. Oussoren, and G. Storm Liposomes to target the lymphatics by subcutaneous administration Adv. Drug Deliv. Rev. 50 2001 143 156
12. C.J. Porter, G.A. Edwards, and S.A. Charman Lymphatic transport of proteins after s.c. injection: implications of animal model selection Adv. Drug Deliv. Rev. 50 2001 157 171
13. A. Supersaxo, W.R. Hein, and H. Steffen Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration Pharm. Res. 7 1990 167 169
14. D.B. Muchmore, and D.E. Vaughn Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase J. Diabetes Sci. Technol. 6 2012 764 772
15. O. Shpilberg, and C. Jackisch Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase Br. J. Cancer 109 2013 1556 1561
16. H.M. Kinnunen, and R.J. Mrsny Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site J. Control. Release 182 2014 22 32
17. A. Ogamo, K. Matsuzaki, H. Uchiyama, and K. Nagasawa Preparation and properties of fluorescent glycosaminoglycuronans labeled with 5-aminofluorescein Carbohydr. Res. 105 1982 69 85
18. M.D. Kay, and et al. Static normothermic preservation of renal allografts using a novel nonphosphate buffered preservation solution Transpl. Int. 20 2007 88 92
19. E.M. Agency Insulin preparations, injectable: European Medicines Agency Eur. Pharmacopoeia 2005 1808 1811
20. K. Aukland, and R.K. Reed Interstitial-lymphatic mechanisms in the control of extracellular fluid volume Physiol. Rev. 73 1993 1 78
21. N. Fogh-Andersen, B.M. Altura, B.T. Altura, and O. Siggaard-Andersen Composition of interstitial fluid Clin. Chem. 41 1995 1522 1525
22. P. Webb Temperatures of skin, subcutaneous tissue, muscle and core in resting men in cold, comfortable and hot conditions Eur. J. Appl. Physiol. Occup. Physiol. 64 1992 471 476
23. H. Noddeland Colloid osmotic pressure of human subcutaneous interstitial fluid sampled by nylon wicks: evaluation of the method Scand. J. Clin. Lab. Invest. 42 1982 123 130
24. H. Noddeland Influence of body posture on transcapillary pressures in human subcutaneous tissue Scand. J. Clin. Lab. Invest. 42 1982 131 138
25. D.T. Birnbaum, S.W. Dodd, B.E. Saxberg, A.D. Varshavsky, and J.M. Beals Hierarchical modeling of phenolic ligand binding to 2Zn-insulin hexamers Biochemistry 35 1996 5366 5378
26. L. Kagan, and D.E. Mager Mechanisms of subcutaneous absorption of rituximab in rats Drug Metab. Dispos. 41 2013 248 255
27. W.F. Richter, and B. Jacobsen Subcutaneous absorption of biotherapeutics: knowns and unknowns Drug Metab. Dispos. 42 2014 1881 1889
28. Y. Zheng, and et al. Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration mAbs 4 2012 243 255
29. J.R. Fraser, T.C. Laurent, and U.B. Laurent Hyaluronan: its nature, distribution, functions and turnover J. Intern. Med. 242 1997 27 33
30. W. Wang, and et al. Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs Drug Metab. Dispos. 40 2012 952 962
31. W. Wang, and et al. Immunogenicity of protein aggregates - concerns and realities Int. J. Pharm. 431 2012 1 11